Beyond the CAR T Cells: TIL Therapy for Solid Tumors

DOI QR Code

Rohit Singh (Immuno-oncology Branch, Division of Rare and Refractory Cancer, National Cancer Center)

Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 2023;20:359-371.
Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-1321.
Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319:1676-1680.
Food and Drug Administration. FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma [Internet]. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma [accessed on 4 March 2024].